Designer probiotics for the prevention and treatment of human diseases

Current Opinion in Chemical Biology

Volumn 40, Issue , 2017, Pages 8-16

  Chua, Koon Jiew ^a,b   Kwok, Wee Chiew ^a,b   Aggarwal, Nikhil ^a,b   Sun, Tao ^a,b   Chang, Matthew Wook ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ALLERGY; AUTOIMMUNE DISEASE; CHEMICAL ENGINEERING; INFECTION; METABOLIC DISORDER; NEOPLASM; REVIEW; SYNTHETIC BIOLOGY; ANIMAL; BACTERIUM; COMMUNICABLE DISEASE; GENETIC ENGINEERING; GENETICS; HUMAN; HYPERSENSITIVITY; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; BACTERIA; COMMUNICABLE DISEASES; GENETIC ENGINEERING; HUMANS; HYPERSENSITIVITY; METABOLIC DISEASES; NEOPLASMS; PROBIOTICS;

EID: 85018760503     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2017.04.011     Document Type: Review

References (66)

1. 1 Tlaskalova-Hogenova, H., Stepankova, R., Hudcovic, T., Tuckova, L., Cukrowska, B., Lodinova-Zadnikova, R., Kozakova, H., Rossmann, P., Bartova, J., Sokol, D., et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol. Lett. 93 (2004), 97–108.
2. 2 Slavin, J., Fiber and prebiotics: mechanisms and health benefits. Nutrients 5 (2013), 1417–1435.
3. 3 Pompei, A., Cordisco, L., Amaretti, A., Zanoni, S., Matteuzzi, D., Rossi, M., Folate production by bifidobacteria as a potential probiotic property. Appl. Environ. Microbiol. 73 (2007), 179–185.
4. 4 McFarland, L.V., Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open, 4, 2014, e005047.
5. 5 Morelli, L., Capurso, L., FAO/WHO guidelines on probiotics: 10 years later. J. Clin. Gastroenterol. 46 (2012), S1–S2.
6. 6 Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., Remaut, E., Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289 (2000), 1352–1355.
7. 7• Duan, F.F., Liu, J.H., March, J.C., Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64 (2015), 1794–1803 The authors had successfully demonstrated the conversion of intestinal cells into insulin-secreting cells, using engineered Lactobacilli that secrete GLP-1. Diabetic rats treated with the engineered microbes showed increased insulin production and glucose tolerance.
8. 8 Rao, S., Hu, S., McHugh, L., Lueders, K., Henry, K., Zhao, Q., Fekete, R.A., Kar, S., Adhya, S., Hamer, D.H., Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 11993–11998.
9. 9 Yang, G., Jiang, Y., Yang, W., Du, F., Yao, Y., Shi, C., Wang, C., Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide. Microb. Cell Fact., 14, 2015, 202.
10. 10 Ma, Y., Liu, J., Hou, J., Dong, Y., Lu, Y., Jin, L., Cao, R., Li, T., Wu, J., Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLoS One, 9, 2014, e105701.
11. 11 Wei, P., Yang, Y., Li, T., Ding, Q., Sun, H., A engineered Bifidobacterium longum secreting a bioative penetratin-glucagon-like peptide 1 fusion protein enhances glucagon-like peptide 1 absorption in the intestine. J. Microbiol. Biotechnol., 24(10), 2014.
12. 12 Zeng, Z., Yu, R., Zuo, F., Zhang, B., Peng, D., Ma, H., Chen, S., Heterologous expression and delivery of biologically active exendin-4 by Lactobacillus paracasei L14. PLoS One, 11, 2016, e0165130.
13. 13• Chen, Z., Guo, L., Zhang, Y., Walzem, R.L., Pendergast, J.S., Printz, R.L., Morris, L.C., Matafonova, E., Stien, X., Kang, L., et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Invest. 124 (2014), 3391–3406 This study demonstrated the effectiveness of the engineered EcN in controlling food intake and weight gain in obese mice.
14. 14 Somabhai, C.A., Raghuvanshi, R., Nareshkumar, G., Genetically engineered Escherichia coli Nissle 1917 synbiotics reduce metabolic effects induced by chronic consumption of dietary fructose. PLoS One, 11, 2016, e0164860.
15. 15 Chaudhari, A.S., Raghuvanshi, R., Kumar, G.N., Genetically engineered Escherichia coli Nissle 1917 synbiotic counters fructose-induced metabolic syndrome and iron deficiency. Appl. Microbiol. Biotechnol., 2017, 10.1007/s00253-017-8207-7.
16. 16 Theuretzbacher, U., Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int. J. Antimicrob. Agents 39 (2012), 295–299.
17. 17 Spellberg, B., Bartlett, J., Wunderink, R., Gilbert, D.N., Novel approaches are needed to develop tomorrow's antibacterial therapies. Am. J. Respir. Crit. Care Med. 191 (2015), 135–140.
18. 18 Saeidi, N., Wong, C.K., Lo, T.M., Nguyen, H.X., Ling, H., Leong, S.S., Poh, C.L., Chang, M.W., Engineering microbes to sense and eradicate Pseudomonas aeruginosa a human pathogen. Mol. Syst. Biol., 7, 2011, 521.
19. 19 Hwang, I.Y., Tan, M.H., Koh, E., Ho, C.L., Poh, C.L., Chang, M.W., Reprogramming microbes to be pathogen-seeking killers. ACS Synth. Biol. 3 (2014), 228–237.
20. 20 Geldart, K., Borrero, J., Kaznessis, Y.N., Chloride-inducible expression cector for delivery of antimicrobial peptides targeting antibiotic-resistant Enterococcus faecium. Appl. Environ. Microbiol. 81 (2015), 3889–3897.
21. 21 Borrero, J., Chen, Y., Dunny, G.M., Kaznessis, Y.N., Modified lactic acid bacteria detect and inhibit multiresistant Enterococci. ACS Synth. Biol. 4 (2015), 299–306.
22. 22 Guo, S., Yan, W., McDonough, S.P., Lin, N., Wu, K.J., He, H., Xiang, H., Yang, M., Moreira, M.A., Chang, Y.F., The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model. Vaccine 33 (2015), 1586–1595.
23. 23 Andersen, K.K., Strokappe, N.M., Hultberg, A., Truusalu, K., Smidt, I., Mikelsaar, R.H., Mikelsaar, M., Verrips, T., Hammarstrom, L., Marcotte, H., Neutralization of Clostridium difficile toxin B mediated by engineered Lactobacilli that produce single-domain antibodies. Infect. Immun. 84 (2015), 395–406.
24. 24 Vishwakarma, V., Sahoo, S.S., Das, S., Ray, S., Hardt, W.D., Suar, M., Cholera toxin-B (ctxB) antigen expressing Salmonella typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection. Vaccine 33 (2015), 1880–1889.
25. 25 Zadravec, P., Mareckova, L., Petrokova, H., Hodnik, V., Perisic Nanut, M., Anderluh, G., Strukelj, B., Maly, P., Berlec, A., Development of recombinant Lactococcus lactis displaying albumin-binding domain variants against Shiga toxin 1 B subunit. PLoS One, 11, 2016, e0162625.
26. 26 Bridge, D.R., Whitmire, J.M., Makobongo, M.O., Merrell, D.S., Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar typhimurium wecA mutant strain. Int. J. Med. Microbiol. 306 (2016), 529–540.
27. 27 Zhang, R., Peng, X., Duan, G., Shi, Q., Chen, S., Wang, C., Fan, Q., Xi, Y., An engineered Lactococcus lactis strain exerts significant immune responses through efficient expression and delivery of Helicobacter pylori Lpp20 antigen. Biotechnol. Lett. 38 (2016), 2169–2175.
28. 28 Zhou, Z., Gong, S., Li, X.M., Yang, Y., Guan, R., Zhou, S., Yao, S., Xie, Y., Ou, Z., Zhao, J., et al. Expression of Helicobacter pylori urease B on the surface of Bacillus subtilis spores. J. Med. Microbiol. 64 (2015), 104–110.
29. 29 Das, K., Thomas, T., Garnica, O., Dhandayuthapani, S., Recombinant Bacillus subtilis spores for the delivery of Mycobacterium tuberculosis Ag85B-CFP 10 secretory antigens. Tuberculosis (Edinb), 2016 S101:S18–S27.
30. 30• Kuczkowska, K., Mathiesen, G., Eijsink, V.G., Oynebraten, I., Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells. Microb. Cell Fact., 14, 2015, 169 The authors modified Lactobacillus to express a chemokine and HIV-1 antigen fusion protein, which successfully enhanced immune responses, illustrating the feasibility of a microbe-based vaccine for HIV.
31. 31 Chamcha, V., Jones, A., Quigley, B.R., Scott, J.R., Amara, R.R., Oral immunization with a recombinant Lactococcus lactis-expressing HIV-1 antigen on Group A Streptococcus pilus induces strong mucosal immunity in the gut. J. Immunol. 195 (2015), 5025–5034.
32. 32 Maddaloni, M., Kochetkova, I., Jun, S., Callis, G., Thornburg, T., Pascual, D.W., Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-beta-producing CD39+ regulatory T cells. PLoS One, 10, 2015, e0117825.
33. 33 Thomas, W.R., Smith, W.-A., Hales, B.J., Mills, K.L., O'Brien, R.M., Characterization and immunobiology of house dust mite allergens. Int. Arch. Allergy Immunol. 129 (2002), 1–18.
34. 34 Ai, C., Zhang, Q., Ren, C., Wang, G., Liu, X., Tian, F., Zhao, J., Zhang, H., Chen, Y.Q., Chen, W., Genetically engineered Lactococcus lactis protect against house dust mite allergy in a BALB/c mouse model. PLoS One, 9, 2014, e109461.
35. 35 Ai, C., Zhang, Q., Ding, J., Ren, C., Wang, G., Liu, X., Tian, F., Zhao, J., Zhang, H., Chen, Y.Q., Suppression of dust mite allergy by mucosal delivery of a hypoallergenic derivative in a mouse model. Appl. Microbiol. Biotechnol. 99 (2015), 4309–4319.
36. 36 Ai, C., Zhang, Q., Ding, J., Wang, G., Liu, X., Tian, F., Zhao, J., Zhang, H., Chen, W., Mucosal delivery of allergen peptides expressed by Lactococcus lactis inhibit allergic responses in a BALB/c mouse model. Appl. Microbiol. Biotechnol. 100 (2016), 1915–1924.
37. 37 del Carmen, S., Martin Rosique, R., Saraiva, T., Zurita-Turk, M., Miyoshi, A., Azevedo, V., de Moreno de LeBlanc, A., Langella, P., Bermudez-Humaran, L.G., LeBlanc, J.G., Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model. J. Clin. Gastroenterol. 48:Suppl 1 (2014), S12–S17.
38. 38 Hanson, M.L., Hixon, J.A., Li, W., Felber, B.K., Anver, M.R., Stewart, C.A., Janelsins, B.M., Datta, S.K., Shen, W., McLean, M.H., et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology, 146, 2014 210–221.e213.
39. 39 Aubry, C., Michon, C., Chain, F., Chvatchenko, Y., Goffin, L., Zimmerli, S.C., Leguin, S., Langella, P., Bermudez-Humaran, L., Chatel, J.M., Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. Microb. Cell Fact., 14, 2015.
40. 40 Shigemori, S., Watanabe, T., Kudoh, K., Ihara, M., Nigar, S., Yamamoto, Y., Suda, Y., Sato, T., Kitazawa, H., Shimosato, T., Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Microb. Cell Fact., 2015, 14.
41. 41 Wei, P., Yang, Y., Liu, Z., Huang, J., Gong, Y., Sun, H., Oral Bifidobacterium longum expressing alpha-melanocyte-stimulating hormone to fight experimental colitis. Drug Deliv. 23 (2016), 2058–2064.
42. 42 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
43. 43 Hoffman, R.M., Zhao, M., Methods for the development of tumor-targeting bacteria. Expert Opin. Drug Discov. 9 (2014), 741–750.
44. 44 Taniguchi, S., Fujimori, M., Sasaki, T., Tsutsui, H., Shimatani, Y., Seki, K., Amano, J., Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Sci. 101 (2010), 1925–1932.
45. 45 Kimura, N.T., Taniguchi, S., Aoki, K., Baba, T., Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40 (1980), 2061–2068.
46. 46 Ashraf, R., Shah, N.P., Immune system stimulation by probiotic microorganisms. Crit. Rev. Food Sci. Nutr. 54 (2014), 938–956.
47. 47 Wei, C., Xun, A.Y., Wei, X.X., Yao, J., Wang, J.Y., Shi, R.Y., Yang, G.H., Li, Y.X., Xu, Z.L., Lai, M.G., et al. Bifidobacteria expressing tumstatin protein for antitumor therapy in tumor-bearing mice. Technol. Cancer Res. Treat. 15 (2016), 498–508.
48. 48 Zhou, H., He, Z., Wang, C., Xie, T., Liu, L., Liu, C., Song, F., Ma, Y., Intravenous administration is an effective and safe route for cancer gene therapy using the Bifidobacterium-mediated recombinant HSV-1 thymidine kinase and ganciclovir. Int. J. Mol. Sci., 17, 2016.
49. 49 Wang, C., Ma, Y., Hu, Q., Xie, T., Wu, J., Zeng, F., Song, F., Bifidobacterial recombinant thymidine kinase-ganciclovir gene therapy system induces FasL and TNFR2 mediated antitumor apoptosis in solid tumors. BMC Cancer, 16, 2016, 545.
50. 50 Yang, Y.W., Zhang, C.M., Huang, X.J., Zhang, X.X., Zhang, L.K., Li, J.H., Hua, Z.C., Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis. Sci. Rep., 6, 2016, 34178.
51. 51 Yoon, W., Park, Y.C., Kim, J., Chae, Y.S., Byeon, J.H., Min, S.H., Park, S., Yoo, Y., Park, Y.K., Kim, B.M., Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. Eur. J. Cancer 70 (2017), 48–61.
52. 52•• Zheng, J.H., Nguyen, V.H., Jiang, S.N., Park, S.H., Tan, W., Hong, S.H., Shin, M.G., Chung, I.J., Hong, Y., Bom, H.S., et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med., 2017, 9 This paper demonstrated the importance of TLR4 and TLR5 in the activation of various lymphocytes to effectively target cancer cells, using engineered Salmonella that expresses flagellin B from Vibrio vulnificus.
53. 53 Swofford, C.A., Van Dessel, N., Forbes, N.S., Quorum-sensing Salmonella selectively trigger protein expression within tumors. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3457–3462.
54. 54• Din, M.O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L.S., Bhatia, S.N., et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536 (2016), 81–85 This study provided insights to better understand quorum-sensing circuit in modified microbes for therapeutic alications.
55. 55•• Camacho, E.M., Mesa-Pereira, B., Medina, C., Flores, A., Santero, E., Engineering Salmonella as intracellular factory for effective killing of tumour cells. Sci. Rep., 6, 2016, 30591 This paper demonstrated the importance of spatial separation of production and release of anti-tumoric agents within host cells.
56. 56 Panteli, J.T., Forkus, B.A., Van Dessel, N., Forbes, N.S., Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. (Camb.) 7 (2015), 423–434.
57. 57 Chen, J.Q., Zhan, Y.F., Wang, W., Jiang, S.N., Li, X.Y., The engineered Salmonella typhimurium inhibits tumorigenesis in advanced glioma. Onco Targets Ther. 8 (2015), 2555–2563.
58. 58 Guo, Z.L., Yu, B., Ning, B.T., Chan, S., Lin, Q.B., Li, J.C., Huang, J.D., Chan, G.C., Genetically modified obligate anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma. J. Hematol. Oncol., 8, 2015, 99.
59. 59 Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J., Bhatia, S.N., Programmable probiotics for detection of cancer in urine. Sci. Transl. Med., 7, 2015, 289ra284.
60. 60• Panteli, J.T., Forbes, N.S., Engineered bacteria detect spatial profiles in glucose concentration within solid tumor cell masses. Biotechnol. Bioeng. 113 (2016), 2474–2484 The authors demonstrated the specificity of glucose-sensing microbes and their potential as drug delivery vehicles.
61. 61 Kasarello, K., Kwiatkowska-Patzer, B., Lipkowski, A.W., Bardowski, J.K., Szczepankowska, A.K., Oral administration of Lactococcus lactis expressing synthetic genes of myelin antigens in decreasing experimental autoimmune encephalomyelitis in rats. Med. Sci. Monit. 21 (2015), 1587–1597.
62. 62 Pinero-Lambea, C., Bodelon, G., Fernandez-Perianez, R., Cuesta, A.M., Alvarez-Vallina, L., Fernandez, L.A., Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth. Biol. 4 (2015), 463–473.
63. 63 Rovner, A.J., Haimovich, A.D., Katz, S.R., Li, Z., Grome, M.W., Gassaway, B.M., Amiram, M., Patel, J.R., Gallagher, R.R., Rinehart, J., et al. Recoded organisms engineered to depend on synthetic amino acids. Nature 518 (2015), 89–93.
64. 64 Mandell, D.J., Lajoie, M.J., Mee, M.T., Takeuchi, R., Kuznetsov, G., Norville, J.E., Gregg, C.J., Stoddard, B.L., Church, G.M., Biocontainment of genetically modified organisms by synthetic protein design. Nature 518 (2015), 55–60.
65. 65• Kotula, J.W., Kerns, S.J., Shaket, L.A., Siraj, L., Collins, J.J., Way, J.C., Silver, P.A., Programmable bacteria detect and record an environmental signal in the mammalian gut. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 4838–4843 This study demonstrates the feasibility of engineering microbes as living diagnostics, enabling further understanding of the symbiotic relationship between commensal microbes and the host.
66. 66 Mimee, M., Tucker, A.C., Voigt, C.A., Lu, T.K., Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst. 1 (2015), 62–71.